




AMCP Publishes 2024 Election Impacts Deck

Following the Nov. 5 general election, AMCP published a deck highlighting the election results and their expected impact on health policy nationwide. The deck includes an overview of the newly elected Republican trifecta in the House of Representatives, Senate, and White House, as well as the results from recent leadership elections in both chambers of Congress. The deck includes the positioning of President-elect Trump's nominations to lead several federal healthcare agencies, including HHS Secretary nominee Robert F. Kennedy Jr. and CMS Administrator nominee Dr. Mehmet Oz. Potential healthcare policy priorities for the incoming administration and Congress are also spotlighted, including Inflation Reduction Act implementation, 340B drug pricing and Pharmacy Benefit Manager reform, reproductive healthcare, telehealth, and site neutral payments. This resource is available only to AMCP members.

[Access the 2024 Election Impacts Deck](#)



State Update: New York Releases Major Market Conduct Regulations for Pharmacy Benefit Managers

On Nov. 21, the New York Department of Financial Services (DFS) announced new regulations for pharmacy benefit managers (PBMs) operating in the state. This new rule implements a major piece of legislation from 2021, [S. 3762/A. 1396](#), which mandated restrictions on PBM contracts and established additional protections for health care consumers. It follows previous efforts to define PBM services, create licensing requirements for PBMs operating in the state, and enact regular reporting requirements. The sweeping DFS rule specifically regulates PBMs' ability to enter into pharmacy network contracts, requires additional pharmacy network and formulary transparency, implements consumer protection incentives, and establishes standards for PBM audits of contract pharmacies.

[Read More About the DFS Rule](#)

AMCP Comments on Medicare \$2 Drug List Model

In October, CMS unveiled a Request for Information (RFI) regarding the Medicare \$2 Drug List Model. The voluntary \$2 drug list model follows a 2022 Executive Order from President Biden that directed HHS to test new policies that would lower prescription drug costs and increase access for patients. The model attempts to standardize cost sharing for low-cost generics through a new, simplified format. The model allows Part D plan sponsors to offer copayments of up to \$2 per month for a standard Medicare-defined list of generic drugs. On Dec. 9, AMCP responded to the RFI with comments commending CMS and the Biden administration's efforts to lower the cost of prescription drugs in the United States. AMCP's comments also applaud the agency's encouragement around low-cost generic adoption but urges CMS to remain vigilant for unintended consequences when developing the model.



[Read AMCP's Comment](#)

What's Next for Health Care Policy in the U.S.?

Last month, Adam Colborn, Associate Vice President of Congressional Affairs at AMCP, sat down with [Managed Healthcare Executive](#) for a debrief on the 2024 elections, as well as anticipated health policy priorities for 2025. The "health policy agenda in Washington is a bit...uncertain," Colborn explains, touching on the uncertainty behind President-elect Trump's cabinet nominations, as well as the severe turnover amongst Members of Congress. "2025 could be a low-volume year for health care policy," Colborn states, adding that "there are still several items that will fight for attention" in the coming lame duck period. That includes several bills affecting managed care pharmacy, including the Equitable Community Access to Pharmacist Services (ECAPS) Act ([H.R. 1770/S. 2477](#)), and PBM reform legislation, while the 2025 session could see movement on the 340B drug discount program, continued implementation of the Inflation Reduction Act, and expansion of value-based purchasing arrangements in state Medicaid programs via the Medicaid VBPs for Patients (MVP) Act ([H.R. 2666/S. 4204](#)).

[Read More](#)